Abstract: TH-PO939
Persistence of Antibody Response to COVID-19 Vaccine in Peritoneal Dialysis (PD) Patients: A Single Center Study
Session Information
- COVID-19: Vaccines and Outcomes ESRD/KTR
November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Rahim, Shab E Gul, Weill Cornell Medicine, New York, New York, United States
- Tummalapalli, Sri Lekha, Weill Cornell Medicine, New York, New York, United States
- Stryjniak, Gabriel J., Weill Cornell Medicine, New York, New York, United States
- Gerardine, Supriya, Weill Cornell Medicine, New York, New York, United States
- Srivatana, Vesh, Rogosin Institute, New York, New York, United States
Background
Published studies on the response to COVID-19 vaccination are primarily focused on hemodialysis. We studied the humoral response to the COVID-19 vaccine in a PD population over a 6 month follow-up period.
Methods
In a retrospective single-center study, we assessed response to COVID-19 vaccination in patients on PD at 4 weeks, 3 months and 6 months after completing the full vaccination series. Response was measured via semiquantitative COVID-19 spike protein total antibody (IgG) level using a chemiluminescent sandwich immunoassay. Antibody (Ab) titers <1 were categorized as no response, 1 to <20 as intermediate, and >20 as high response. Chi-squared tests for categorical variables and unadjusted linear regression for continuous variables were used to compare characteristics among responders vs non-responders.
Results
Of 119 patients on PD who received COVID-19 vaccine as of December 2021, 108/119 (91%) had a positive Ab response and 11/119 (9%) had no response. A total of 37% had an intermediate and 53.7% had a high response. Positive COVID-19 serology prior to vaccination (p= 0.010) as well as type of vaccine (p=0.032) were associated with higher Ab response in univariate analyses. Other factors were not statistically significantly associated with Ab response. Among the 73 participants with Ab levels at all timepoints, at 4 weeks, 11 (15%) had no Ab response, 19 (26%) intermediate, and 43 (59%) high response. At 3 months, 12 (16%) of participants had no Ab response, 27 (37%) intermediate, and 34 (47%) high response. At 6 months, 12 (16%) of participants had no Ab response, 38 (52%) intermediate, and 23 (32%) high response.
Conclusion
Most PD patients developed a positive Ab response to the COVID-19 vaccine. Positive COVID-19 serology prior to vaccination and the type of vaccine received were associated with higher Ab response. Our data suggests promising COVID-19 vaccine response among PD patients.
Characteristics of Patients Receiving Peritoneal Dialysis by COVID-19 Antibody Response